December 9th 2024
Protocol-defined transfusion independence (TI) was achieved by 52 of the 63 patients in long-term follow-up study LTF-303.
Navigating the Next Wave in BTK Inhibition Strategies: Maximizing Clinical Benefit in CLL and MCL, What’s Next...
December 14, 2024
Register Now!
Oncology Town Hall™: Primary Investigators Present Key Abstracts in CLL from San Diego
View More
Understanding the Recent Developments in Myelodysplastic Syndromes (MDS)
View More
Focusing on Key Updates on the Outlook of Acute Lymphocytic Leukemia (ALL) Management
View More
Experts Address the Hottest Topics in AML: Considerations on FLT3, IDH1/2, TP53, Maintenance, Novel Combinations and Beyond!
View More
Medical Crossfire®: Novel BTKi Strategies Transforming Aggressive and Indolent B-Cell Malignancies
View More
The Latest Advancements in the Treatment of Chronic Myeloid Leukemia (CML)
View More
The Effect of Recent Updates on the Outlook of Acute Myeloid Leukemia (AML) Management
View More
FDA Announces Probe Into bluebird's Elivaldogene Autotemcel for Hematologic Malignancies
Approved as Skysona, the therapy has been reported to be related to cases of hematologic malignancies, including life-threatening instances of myelodysplastic syndrome and acute myeloid leukemia.
First Patient Dosed in RIDGE-1 Trial for Tenaya’s ARV Cardiomyopathy Gene Therapy TN-401
November 26th 2024The patient’s dosing took place at the University of California, San Francisco, although the multicenter study is expected to eventually dose patients at other locations in the United States, United Kingdom, and Europe.
Alzheimer Disease Awareness Month 2024: Looking Back at a Year of Progress in Cell and Gene Therapy
November 24th 2024In observance of Alzheimer Disease Awareness Month, held annually in November, we took a look back at the past year's news and expert insights in cell and gene therapy for Alzheimer disease.
Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
November 21st 2024Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center, discussed interim data from the phase 1/1b clinical trial evaluating Poseida's CAR-T.